**Research in the Prairie State**

**Astellas and University of Chicago, Chicago, IL**
Astellas is conducting a phase II clinical trial at University of Chicago to test the safety and efficacy of the antibody ASKP1240. Researchers will observe whether adding this compound to a commonly deployed post-kidney transplant drug regimen will reduce the risk of organ rejection.

**The University of Chicago, Chicago, IL**
Researchers at the University of Chicago have secured funding from the Agency for Healthcare Research and Quality (AHRQ) to study the factors that influence patients’ treatment decisions in order to improve health care outcomes for chronic hepatitis C, which affects as many as 3.9 million Americans.

**The University of Illinois at Chicago, Chicago, IL**
The National Institutes of Health (NIH) is funding a study at the University of Illinois at Chicago to develop a novel therapeutic method for brain stimulation in stroke survivors. This study hopes to increase gait rehabilitation in survivors and discover the neural mechanisms involved in both impairment and recovery from stroke.

*SOURCES:* NATIONAL INSTITUTES OF HEALTH (NIH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), A RESEARCH AMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JANUARY 2017, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ), CLINICALTRIALS.GOV, AMERICAN DIABETES ASSOCIATION.